Tessera Defense and Homeland Security Inc. PHGE
1.85 USD +0.23 (+14.20%)
At closeSep 10, 2026, 4:00 PM EDT
0.41 -1.44 -77.68%
After hours · Sep 10, 4:00 PM ET
1.65 Day range 2.16
0.1192 52-week range 8.50
- YTD
- -1.07%
- 1 year
- -78.36%
- Market cap
- 5.00M
- Shares out
- 18.18M
- YTD return
- -1.07%
- 1-year return
- -78.36%
- Volume
- 3.27M
- Avg volume
- 364.37K
- Open
- 1.66
- Previous close
- 1.62
- Day's range
- 1.65 – 2.16
- 52-week range
- 0.1192 – 8.50
- Beta
- 1.32
- Price target
- 7.00 (+278.4%)
- Earnings date
- Aug 14, 2024
2Y -0.2365 (-44.79%)
Key statistics
- Enterprise value
- 24.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.37M
- Total cash
- 31.61M
- Total debt
- 9.90M
- Return on equity
- -121.29%
- Short % of float
- 0.15%
- 50-day average
- 0.7297
- 200-day average
- 2.23
Analyst view
Price target (mean) 7.00 +278.4% upside
Now 1.85
- Target (low)
- 2.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -1.10.
Financials — quick view
PHGE Revenue — quarterly 332.00K
PHGE Net income — quarterly -3.77M
PHGE EPS — quarterly -3.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -0.97 | -0.37 | -61.67% |
| Aug 14, 2024 | Jun 1, 2024 | -1.20 | 0.70 | +1.90 | +158.33% |
| Aug 14, 2024 | Jun 1, 2024 | -1.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.70 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.70 | -1.50 | -0.80 | -114.29% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 28, 2024 | Laidlaw & Co. | init | — | Buy |
| May 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Tessera Defense and Homeland Security Inc.
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biomx.com
News
Tessera Defense and Homeland Security CEO Issues Letter to Shareholders 
BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows 
BiomX Inc. to Become Tessera Defense and Homeland Security Inc. 
Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Fall as US-Iran Tensions Flare Up—WMT, RZLV, FNGR in Focus (UPDATED) 
SAIC, Walmart And 3 Stocks To Watch Heading Into Monday 
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site 
BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems 
BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
Your note
Sign in to keep a note on PHGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASSAN MARAV | Officer | Stock Award(Grant) | Sep 15, 2024 | 31,749 |
| CYSTIC FIBROSIS FOUNDATION | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2024 | 9,330,580 |
| FLYNN JAMES E | Director | Conversion of Exercise of derivative security | Jul 14, 2024 | 0 |
| ORBIMED ISRAEL BIOFUND GP, L. P. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 14, 2024 | 0 |
| ORON ASSAF | Officer | Stock Award(Grant) | Sep 15, 2024 | 25,804 |
| SOLOMON JONATHAN EITAN | Chief Executive Officer | Stock Award(Grant) | Sep 15, 2024 | 53,056 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 9.84% | 1,787,767 | 983.27K | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 9.83% | 1,787,610 | 983.18K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 9.52% | 1,730,600 | 951.83K | Sep 29, 2024 |
| Ikarian Capital, LLC | 4.91% | 893,000 | 491.15K | Sep 29, 2024 |
| AIGH Capital Management LLC | 4.76% | 865,400 | 475.97K | Sep 29, 2024 |
| Heights Capital Management, Inc | 3.24% | 589,027 | 323.96K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.07% | 49,500 | 27.23K | Dec 30, 2023 |